A Phase 1 interventional study of Treatment A: Doravirine 100 mg film coated tablet and Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) in Human Immunodeficiency Virus-1 (HIV-1), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate and compare the relative bioavailability of different doravirine (MK-1439) experimental nano formulations (NFs) with that of a doravirine film coated tablet.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet \[40% drug loaded granule\]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet \[30% drug loaded granule\]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet \[50% drug loaded granule\]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet \[30% drug loaded granule\]). Each period was separated by a 14 day washout.
Drug: Treatment A: Doravirine 100 mg film coated tablet · Drug: Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) · Drug: Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) · Drug: Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) · Drug: Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)
Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
Also known as: MK-1439
Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
Also known as: MK-1439
Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
Also known as: MK-1439
Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
Also known as: MK-1439
Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
Also known as: MK-1439
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.
Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.
Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.
Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439
During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.
Time frame: Periods 1 to 5: 24 hours post-dose
Number of Participants Who Experienced at Least One Adverse Event
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.
Time frame: Up to 16 days after last dose of study treatment (up to approximately 92 days)
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.
Time frame: Up to 4 days after last dose of study treatment (up to approximately 76 days)
Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.
Time frame: Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose
| Milestone | MK-1439 Fixed Sequence Treatment |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | MK-1439 Fixed Sequence Treatment |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | MK-1439 Fixed Sequence Treatment |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | MK-1439 Fixed Sequence Treatment |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | MK-1439 Fixed Sequence Treatment |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.
| µM*h | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439 | 28.6 ± 34.6 | 31.9 ± 33.9 | 35.5 ± 29.6 | 29.1 ± 30.3 | 28.0 ± 27.5 |
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.
| μM*h | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439 | 26.3 ± 29.3 | 29.9 ± 31.1 | 32.7 ± 26.3 | 27.0 ± 28.4 | 26.3 ± 27.0 |
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.
| nM | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439 | 1070 ± 26.5 | 1520 ± 32.5 | 1320 ± 27.8 | 1060 ± 27.0 | 1160 ± 24.2 |
During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.
| nM | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439 | 395 ± 31.9 | 483 ± 33.3 | 508 ± 23.2 | 412 ± 28.0 | 402 ± 32.0 |
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.
| Participants | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event | 2 | 5 | 4 | 6 | 1 |
An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.
| Participants | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an Adverse Event | 0 | 0 | 0 | 0 | 0 |
During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.
| µM*h | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439 | 22.8 ± 27.5 | 27.2 ± 29.2 | 28.8 ± 24.8 | 23.2 ± 27.3 | 23.3 ± 25.9 |
Collected over Up to 16 days following the last dose of study treatment (up to approximately 92 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Treatment A: MK-1439 100 mg Film Coated Tablet | 0/16 (0%) | 0/16 (0%) | 5/16 (31.3%) |
| Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Event | Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule) | Treatment A: MK-1439 100 mg Film Coated Tablet | Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule) | Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule) | Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/16 | 2/16 | 2/16 | 3/16 | 0/16 |
| NasopharyngitisInfections and infestations | 0/16 | 2/16 | 0/16 | 0/16 | 0/16 |
| LacerationInjury, poisoning and procedural complications | 0/16 | 0/16 | 2/16 | 0/16 | 0/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/16 | 0/16 | 0/16 | 2/16 | 0/16 |
| Vision blurredEye disorders | 0/16 | 1/16 | 0/16 | 0/16 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 0/16 | 1/16 | 0/16 | 1/16 |
| ToothacheGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 0/16 |
| Feeling of body temperture changeGeneral disorders | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 |
| Skin abrasionInjury, poisoning and procedural complications | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 |
| Age, Continuous(years) | MK-1439 Fixed Sequence Treatment |
|---|---|
| Mean | 41.8 ± 9.48 |
| Sex: Female, Male(Participants) | MK-1439 Fixed Sequence Treatment |
|---|---|
| Female | 6 |
| Male | 10 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Sep 2015 to primary completion in Dec 2015, 3 months.
Results were first posted in Feb 2019, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doravirine